Suchergebnisse - "Othman, Jad"

PubPharm (34)

1

Chronic myeloproliferative neoplasm in adulthood in CBL syndrome harboring a splice-site CBL variant alongside a novel constitutional CSF3R variant

enthalten in: EJHaem | 2024

von Mason, G. | Aghajani, R. | Dance, B. | +4

2

Peripheral Blood Haploidentical Allogeneic Stem Cell Transplantation in Older Adults with Acute Myeloid Leukemia and Myelodysplastic Syndromes Demonstrates Long Term Survival, Results from Australia and New Zealand Transplant and Cellular Therapies

enthalten in: Transplantation and cellular therapy | 2024

von Abadir, E. | Othman, J. | Kwan, J. | +12

3

Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Russell, N. | Wilhelm-Benartzi, C. | Othman, J. | +117

4

Post induction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission

enthalten in: Blood | 2024

von Othman, J. | Potter, N. | Ivey, A. | +17

5

Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy

enthalten in: Blood | 2024

von Othman, J. | Tiong, I. | O'Nions, J. | +33

CommentIn: Blood. 2024 Jan 25;143(4):296-298. - PMID 38270942

6

Venetoclax-based low intensity therapy in molecular failure of NPM1-mutated AML

enthalten in: Blood advances | 2024

von Jimenez-Chillon, C. | Othman, J. | Taussig, D. | +29

7

Long-term outcomes of corticosteroid graft versus host disease prophylaxis in peripheral blood allogeneic haemopoietic stem cell transplant : a comparative cohort analysis

enthalten in: Internal medicine journal | 2023

von Blennerhassett, R. | Othman, J. | Biscoe, A. | +18

8

FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML

enthalten in: Leukemia | 2023

von Othman, J. | Potter, N. | Mokretar, K. | +35

9

A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS : the UK NCRI AML19 trial

enthalten in: Blood advances | 2023

von Othman, J. | Wilhelm-Benartzi, C. | Dillon, R. | +19

10

Time to add gemtuzumab ozogamicin to intensive chemotherapy for NPM1-mutated acute myeloid leukaemia?

enthalten in: The Lancet. Haematology | 2023

von Othman, J. | Dillon, R.

CommentOn: Lancet Haematol. 2023 Jul;10(7):e495-e509. - PMID 37187198